{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:23:49Z","timestamp":1772249029584,"version":"3.50.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Microbiology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.tim.2009.08.006","type":"journal-article","created":{"date-parts":[[2009,9,25]],"date-time":"2009-09-25T16:43:37Z","timestamp":1253897017000},"page":"522-528","source":"Crossref","is-referenced-by-count":34,"title":["Medical countermeasures to protect humans from anthrax bioterrorism"],"prefix":"10.1016","volume":"17","author":[{"given":"Dimitrios G.","family":"Bouzianas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tim.2009.08.006_bib1","unstructured":"US Department of Health and Human Services, National Institute of Allergy and Infectious Diseases (NIAID), Biodefense Research Agenda for CDC Category A Agents: 2006 Progress Report, pp. 15\u201323."},{"key":"10.1016\/j.tim.2009.08.006_bib2","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1001\/jama.287.17.2236","article-title":"Anthrax as a biological weapon \u2013 updated recommendations for management","volume":"287","author":"Inglesby","year":"2002","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.tim.2009.08.006_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-9433-4-4","article-title":"Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin","volume":"4","author":"Wang","year":"2005","journal-title":"Med. Immunol."},{"key":"10.1016\/j.tim.2009.08.006_bib4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.7326\/0003-4819-142-8-200504190-00016","article-title":"Being Prepared: Modeling the Response to an Anthrax Attack","volume":"142","author":"Webb","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tim.2009.08.006_bib5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF03160961","article-title":"Analysis of suspicious powders following the post 9\/11 anthrax scare","volume":"4","author":"Wills","year":"2008","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.tim.2009.08.006_bib6","first-page":"234","article-title":"Anthrax: a continuing concern in the era of bioterrorism","volume":"18","author":"Riedel","year":"2005","journal-title":"BUMC Proc."},{"key":"10.1016\/j.tim.2009.08.006_bib7","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1126\/science.7973702","article-title":"The Sverdlovsk anthrax outbreak of 1979","volume":"266","author":"Meselson","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.tim.2009.08.006_bib8","series-title":"Health Aspects of Chemical and Biological Weapons","year":"1970"},{"key":"10.1016\/j.tim.2009.08.006_bib9","unstructured":"Office of Technology Assessment, US Congress (1993) Proliferation of Weapons of Mass Destruction, pp. 53\u201355, US Government Printing Office"},{"key":"10.1016\/j.tim.2009.08.006_bib10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1586\/14787210.5.4.665","article-title":"Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism","volume":"5","author":"Bouzianas","year":"2007","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"10.1016\/j.tim.2009.08.006_bib11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1146\/annurev.micro.61.080706.093224","article-title":"Structure, assembly, and function of the spore surface layers","volume":"61","author":"Henriques","year":"2007","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.tim.2009.08.006_bib12","doi-asserted-by":"crossref","first-page":"30945","DOI":"10.1074\/jbc.M401613200","article-title":"Novel oligosaccharide side chains of the collagen-like region of BclA, the major glycoprotein of the Bacillus anthracis exosporium","volume":"279","author":"Daubenspeck","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tim.2009.08.006_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nature01586","article-title":"The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria","volume":"423","author":"Read","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.tim.2009.08.006_bib14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1128\/IAI.74.1.469-480.2006","article-title":"Roles of macrophages and neutrophils in the early host response to Bacillus anthracis spores in a mouse model of infection","volume":"74","author":"Cote","year":"2006","journal-title":"Infect. Immun."},{"key":"10.1016\/j.tim.2009.08.006_bib15","doi-asserted-by":"crossref","first-page":"7994","DOI":"10.4049\/jimmunol.178.12.7994","article-title":"Lung dendritic cells rapidly mediate anthrax spore entry through the pulmonary route","volume":"178","author":"Cleret","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.tim.2009.08.006_bib16","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJM199909093411107","article-title":"Anthrax","volume":"341","author":"Dixon","year":"1999","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.tim.2009.08.006_bib17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1164\/rccm.200608-1239CP","article-title":"Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy","volume":"175","author":"Sherer","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.tim.2009.08.006_bib18","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0002-9440(10)62496-0","article-title":"Anthrax lethal toxin induces endothelial barrier dysfunction","volume":"166","author":"Warfel","year":"2005","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tim.2009.08.006_bib19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.it.2006.07.002","article-title":"Anthrax toxins: a paradigm of bacterial immune suppression","volume":"27","author":"Baldari","year":"2006","journal-title":"Trends Immunol."},{"key":"10.1016\/j.tim.2009.08.006_bib20","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-2672.2006.03112.x","article-title":"Past, imminent and future human medical countermeasures for anthrax","volume":"101","author":"Baillie","year":"2006","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.tim.2009.08.006_bib21","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.addr.2005.01.028","article-title":"Molecular basis for improved anthrax vaccines","volume":"57","author":"Brey","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.tim.2009.08.006_bib22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/0272989X07312721","article-title":"Modeling the logistics of response to anthrax bioterrorism","volume":"28","author":"Zaric","year":"2008","journal-title":"Med. Decis. Making."},{"key":"10.1016\/j.tim.2009.08.006_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1086\/523578","article-title":"Countering anthrax: vaccines and immunoglobulins","volume":"46","author":"Grabenstein","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2009.08.006_bib24","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2105\/AJPH.2006.102749","article-title":"Anthrax vaccine and public health policy","volume":"97","author":"Weiss","year":"2007","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.tim.2009.08.006_bib25","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1128\/IAI.00315-06","article-title":"Additional conjugation methods and immunogenicity of Bacillus anthracis poly-\u03b3-D-glutamic acid-protein conjugates","volume":"74","author":"Kubler-Kielb","year":"2006","journal-title":"Infect. Immun."},{"key":"10.1016\/j.tim.2009.08.006_bib26","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1074\/jbc.M509432200","article-title":"Immunogenicity and protective efficacy of Bacillus anthracis poly-\u03b3-D-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy","volume":"281","author":"Joyce","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tim.2009.08.006_bib27","doi-asserted-by":"crossref","first-page":"10925","DOI":"10.1073\/pnas.1834478100","article-title":"A dually active anthrax vaccine that confers protection against both bacilli and toxins","volume":"100","author":"Rhie","year":"2003","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"10.1016\/j.tim.2009.08.006_bib28","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1016\/j.vaccine.2006.01.054","article-title":"Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series","volume":"24","author":"Pittman","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.tim.2009.08.006_bib29","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1016\/j.vaccine.2008.05.068","article-title":"An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals","volume":"26","author":"Hewetson","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.tim.2009.08.006_bib30","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jama.300.13.1532","article-title":"Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial","volume":"300","author":"Marano","year":"2008","journal-title":"J. Am. Med. Assoc"},{"key":"10.1016\/j.tim.2009.08.006_bib31","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/01.jom.0000058345.05741.6b","article-title":"Analysis of adverse events after anthrax immunization in US army medical personnel","volume":"4","author":"Wasserman","year":"2003","journal-title":"J. Occup. Environ. Med."},{"key":"10.1016\/j.tim.2009.08.006_bib32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1586\/14760584.5.4.417","article-title":"Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine","volume":"5","author":"Keitel","year":"2006","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.tim.2009.08.006_bib33","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.vaccine.2005.10.018","article-title":"A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection","volume":"24","author":"Hepler","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.tim.2009.08.006_bib34","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.vaccine.2006.05.044","article-title":"Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial","volume":"24","author":"Gorse","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.tim.2009.08.006_bib35","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1128\/IAI.73.9.5978-5987.2005","article-title":"Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax","volume":"73","author":"Williamson","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.tim.2009.08.006_bib36","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.vaccine.2006.07.037","article-title":"Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigen","volume":"25","author":"Duc le","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.tim.2009.08.006_bib37","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1128\/IAI.01722-07","article-title":"Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant","volume":"76","author":"Park","year":"2008","journal-title":"Infect. Immun."},{"key":"10.1016\/j.tim.2009.08.006_bib38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jps.20484","article-title":"Anthrax vaccine powder formulations for nasal mucosal delivery","volume":"95","author":"Jiang","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.tim.2009.08.006_bib39","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1086\/422694","article-title":"Induction of protective immunity against lethal anthrax challenge with a patch","volume":"190","author":"Kenney","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2009.08.006_bib40","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1128\/IAI.01242-06","article-title":"Oral administration of a Salmonella-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis","volume":"75","author":"Stokes","year":"2007","journal-title":"Infect. Immun."},{"key":"10.1016\/j.tim.2009.08.006_bib41","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.virol.2006.05.010","article-title":"Rabies virus glycoprotein as a carrier for anthrax protective antigen","volume":"353","author":"Smith","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.tim.2009.08.006_bib42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.tibtech.2006.06.006","article-title":"Engineered chloroplasts as vaccine factories to combat bioterrorism","volume":"24","author":"Streatfield","year":"2006","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.tim.2009.08.006_bib43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/mt.2008.242","article-title":"Genetic vaccines for anthrax based on recombinant adeno-associated virus vectors","volume":"17","author":"Liu","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tim.2009.08.006_bib44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.mt.6300034","article-title":"Adenovirus-based prime\u2013boost immunization for rapid vaccination against anthrax","volume":"15","author":"McConnell","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tim.2009.08.006_bib45","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1099\/mic.0.2007\/008292-0","article-title":"Analysis of a novel spore antigen in Bacillus anthracis that contributes to spore opsonization","volume":"154","author":"Cote","year":"2008","journal-title":"Microbiology"},{"key":"10.1016\/j.tim.2009.08.006_bib46","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1128\/AAC.00741-07","article-title":"Treatment of experimental anthrax with recombinant capsule depolymerase","volume":"52","author":"Scorpio","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2009.08.006_bib47","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2180-6-56","article-title":"The Bacillus anthracis cholesterol-dependent cytolysin, anthrolysin O, kills human neutrophils, monocytes and macrophages","volume":"6","author":"Mosser","year":"2006","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.tim.2009.08.006_bib48","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1128\/IAI.02029-06","article-title":"Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome","volume":"75","author":"Chitlaru","year":"2007","journal-title":"Infect. Immun."},{"key":"10.1016\/j.tim.2009.08.006_bib49","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1128\/IAI.00261-07","article-title":"Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax","volume":"75","author":"Albrecht","year":"2007","journal-title":"Infect Immun."},{"key":"10.1016\/j.tim.2009.08.006_bib50","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.vaccine.2005.01.013","article-title":"Human-derived, plant-produced monoclonal antibody for the treatment of anthrax","volume":"23","author":"Hull","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.tim.2009.08.006_bib51","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1128\/MMBR.68.4.617-629.2004","article-title":"Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines","volume":"68","author":"Phipps","year":"2004","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.tim.2009.08.006_bib52","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1128\/IAI.00520-08","article-title":"Identification of a surrogate marker for infection in the African green monkey model of inhalation anthrax","volume":"76","author":"Rossi","year":"2008","journal-title":"Infect. Immun."},{"key":"10.1016\/j.tim.2009.08.006_bib53","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1128\/IAI.01133-06","article-title":"Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule","volume":"75","author":"Kozel","year":"2007","journal-title":"Infect. Immun."},{"key":"10.1016\/j.tim.2009.08.006_bib54","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1128\/IAI.73.2.795-802.2005","article-title":"A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge","volume":"73","author":"Mohamed","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.tim.2009.08.006_bib55","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/500148","article-title":"Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen","volume":"193","author":"Chen","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2009.08.006_bib56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1086\/430708","article-title":"A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen in healthy volunteers","volume":"41","author":"Subramanian","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2009.08.006_bib57","doi-asserted-by":"crossref","first-page":"270","DOI":"10.7326\/0003-4819-144-4-200602210-00009","article-title":"Systematic review: a century of inhalational anthrax cases from 1900 to 2005","volume":"144","author":"Holty","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tim.2009.08.006_bib58","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/138920108783497604","article-title":"Discovery and development of anthrax lethal factor metalloproteinase inhibitors","volume":"9","author":"Turk","year":"2008","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.tim.2009.08.006_bib59","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bioorg.2006.07.004","article-title":"Mechanistic differences between in vitro assays for hydrazone-based small molecule inhibitors of anthrax lethal factor","volume":"35","author":"Hanna","year":"2007","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.tim.2009.08.006_bib60","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nature03087","article-title":"Public health vaccination policies for containing an anthrax outbreak","volume":"432","author":"Brookmeyer","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.tim.2009.08.006_bib61","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1046\/j.1469-0691.2002.00527.x","article-title":"Bacillus anthracis and antibacterial agents","volume":"8","author":"Bryskier","year":"2002","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.tim.2009.08.006_bib62","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nchembio.2007.24","article-title":"Targeting virulence: a new paradigm for antimicrobial therapy","volume":"3","author":"Clatworthy","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.tim.2009.08.006_bib63","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1128\/IAI.59.10.3472-3477.1991","article-title":"Berche P, Mock M. Contribution of individual toxin components to virulence of Bacillus anthracis","volume":"59","author":"Pezard","year":"1991","journal-title":"Infect. Immun."},{"key":"10.1016\/j.tim.2009.08.006_bib64","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2174\/138955708783744083","article-title":"Low molecular weight inhibitors of the protease anthrax lethal factor","volume":"8","author":"Dalkas","year":"2008","journal-title":"Mini. Rev. Med. Chem."},{"key":"10.1016\/j.tim.2009.08.006_bib65","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1021\/mp8000149","article-title":"Combating the threat of anthrax: a quantitative structure-activity relationship approach","volume":"5","author":"Verma","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.tim.2009.08.006_bib66","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1021\/jm0605132","article-title":"Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening","volume":"49","author":"Schepetkin","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tim.2009.08.006_bib67","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bioorg.2006.12.005","article-title":"A high-throughput screening approach to anthrax lethal factor inhibition","volume":"35","author":"Johnson","year":"2007","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.tim.2009.08.006_bib68","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1747-0285.2007.00617.x","article-title":"Rhodanine derivatives as selective protease inhibitors against bacterial toxins","volume":"71","author":"Johnson","year":"2008","journal-title":"Chem. Biol. Drug. Des."},{"key":"10.1016\/j.tim.2009.08.006_bib69","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1086\/510856","article-title":"Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model","volume":"195","author":"Cui","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2009.08.006_bib70","doi-asserted-by":"crossref","first-page":"7813","DOI":"10.1073\/pnas.0602748103","article-title":"Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax","volume":"103","author":"Vietri","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tim.2009.08.006_bib71","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3201\/eid0810.020349","article-title":"Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence","volume":"8","author":"Shepard","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.tim.2009.08.006_bib72","doi-asserted-by":"crossref","first-page":"601","DOI":"10.7326\/0003-4819-142-8-200504190-00008","article-title":"Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax","volume":"142","author":"Fowler","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tim.2009.08.006_bib73","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2353\/ajpath.2006.051330","article-title":"Sepsis and pathophysiology of anthrax in a nonhuman primate model","volume":"169","author":"Stearns-Kurosawa","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tim.2009.08.006_bib74","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1016\/j.vaccine.2005.08.031","article-title":"DNA vaccination against anthrax in mice\u2013combination of anti-spore and anti-toxin components","volume":"24","author":"Hahn","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.tim.2009.08.006_bib75","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.biochem.75.103004.142728","article-title":"Anthrax toxin: receptor binding, internalization, pore formation and translocation","volume":"76","author":"Young","year":"2007","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.tim.2009.08.006_bib76","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1128\/MMBR.68.3.373-402.2004","article-title":"Binary bacterial toxins: biochemistry, biology and applications of common Clostridium and Bacillus proteins","volume":"68","author":"Barth","year":"2004","journal-title":"Microbiol. Mol. Biol. Rev."}],"container-title":["Trends in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966842X09001711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966842X09001711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T13:31:53Z","timestamp":1590154313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966842X09001711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":76,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0966842X09001711"],"URL":"https:\/\/doi.org\/10.1016\/j.tim.2009.08.006","relation":{},"ISSN":["0966-842X"],"issn-type":[{"value":"0966-842X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}